丁型肝炎病毒临床试验:如何衡量成功
慢性丁型肝炎是最严重的慢性病毒性肝炎,目前缺乏有效治疗。聚乙二醇干扰素α虽被主要肝病学会推荐用于有限疗程,但持续病毒学应答率低且易复发。新型药物如bulevirtide、lonafarnib、聚乙二醇干扰素λ和REP-2139正在评估中,但终点指标差异大。美国食品药品监督管理局建议采用替代终点预测长期临床获益,但最佳衡量成功的方法仍未知。
要点
- 慢性丁型肝炎是最严重的慢性病毒性肝炎,目前缺乏有效治疗。
- 聚乙二醇干扰素α被主要肝病学会推荐用于有限疗程,但持续病毒学应答率低且易复发。
- 美国食品药品监督管理局建议采用替代终点预测长期临床获益,但最佳衡量成功的方法仍未知。
核心结论
- 丁型肝炎病毒临床试验中衡量成功的最佳方法仍未知,并将继续演变。
研究设计与样本
- 本文为综述,未报告系统检索范围。
主要发现
- 聚乙二醇干扰素α治疗持续病毒学应答率低,即使达到持续病毒学应答也频繁复发。
- 新型研究性药物包括bulevirtide、lonafarnib、聚乙二醇干扰素λ和REP-2139。
- 近期引入的终点之一为丁型肝炎病毒RNA下降2 log,伴或不伴血清丁型肝炎病毒RNA检测不到,作为病毒学应答标志。
- 该指标与丙氨酸氨基转移酶正常化(即生化应答)联合,构成多项后期研究的主要终点。
关键数值与推荐
- 美国食品药品监督管理局近期指导认为,这些应为替代终点,最终预示长期临床获益。
- 长期临床获益可能包括降低进展为肝硬化、肝功能失代偿、肝细胞癌、肝移植和死亡的风险。
临床怎么用
- 原文未据此给出推荐。
局限性
- 丁型肝炎病毒临床试验中衡量成功的最佳方法仍未知,并将继续演变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic hepatitis D infection results in the most severe form of chronic viral hepatitis but currently lacks effective treatment options. Therapy with pegylated interferon alpha is recommended for finite treatment duration by major liver societies. Still, it is plagued by low rates of sustained virologic response (SVR) and frequent relapses even if SVR is achieved. Recently, a wave of investigational therapies has come under evaluation, including bulevirtide, lonafarnib, pegylated interferon lambda, and REP-2139 creating excitement with this viral infection. However, there has been significant variability in the endpoints used to evaluate these therapeutics. One of the recently introduced endpoints is characterized by a decline in HDV RNA by 2 logs, with or without achieving an undetectable serum hepatitis D virus (HDV) RNA, as a marker of virologic response. Furthermore, this measure has been combined with alanine aminotransferase normalization, also known as a biochemical response, to formulate the primary endpoint of several late-stage studies. Per recent guidance by the US Food and Drug Administration, these should be surrogate endpoints that will ultimately portend long-term clinical benefits. These clinical benefits may include reducing the risk of progression to cirrhosis, hepatic decompensation, hepatocellular carcinoma, liver transplantation, and mortality. However, the optimal way to measure success in HDV clinical trials remains unknown and will continue to evolve.
引用
- Da BL. Clinical trials in hepatitis D virus: Measuring success. Hepatology. 2022. PMID: 35969089. doi:10.1002/hep.32732
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。